Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.
| Revenue (Most Recent Fiscal Year) | $0.65M |
| Net Income (Most Recent Fiscal Year) | $-98.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -94.65% |
| Return on Assets (Trailing 12 Months) | -73.36% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.60 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.09 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.00M |
| Free Float | 51.14M |
| Market Capitalization | $261.91M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | 1.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |